Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Fluorescence-based assay for detecting SARS-CoV-2 neutralizing antibodies

Researchers have developed a rapid assay to rapidly detect neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using an imaging technique they developed for the Ebola virus.

8 Jun 2021

Experimental monoclonal antibody could be a new weapon against HIV epidemic

An experimental, lab-made antibody can completely prevent nonhuman primates from being infected with the monkey form of HIV, new research published in Nature Communications shows.

7 Jun 2021

The great promise of antiviral peptides against SARS-CoV-2

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

7 Jun 2021

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

A recent study conducted by a team of scientists in the Netherlands has revealed that while severely affected hospitalized COVID-19 patients and vaccinated individuals are capable of neutralizing the B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2, a significant proportion of non-hospitalized patients with less severe COVID-19 remain susceptible to these viral variants.

2 Jun 2021

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the world's largest clinical cancer research meeting.

1 Jun 2021

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

The U.S. Food and Drug Administration (FDA) has given the green light on the investigational monoclonal antibody therapy, sotrovimab, as a coronavirus disease (COVID-19) treatment.

1 Jun 2021

Using Sotrovimab to treat COVID-19 early

A new study published on the medRxiv* preprint server hypothesized that a monoclonal antibody that has the capability to neutralize all sarbecoviruses could also be used to target a highly conserved epitope. This conserved sequence has a high probability of remaining unchanged in SARS-CoV-2 variants.

31 May 2021

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.

31 May 2021

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

A team of scientists from France has recently conducted a study to evaluate the sensitivity of the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to antibody-mediated neutralization.

31 May 2021

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

A new study by researchers from Taiwan and the US suggests that the removal of unnecessary glycans from spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposes highly conserved sequences and opens the door for the development of broadly protective vaccines against the virus and its variants.

28 May 2021

Reducing COVID-19 burden with monoclonal antibodies and vaccination

Researchers in the United States, the UK and France have shown that using antiviral monoclonal antibodies in combination with vaccination can be expected to suppress the transmission of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) and reduce the burden of coronavirus disease 2019 (COVID-19) more than vaccination alone.

26 May 2021

Could GRP78 be a therapeutic target against COVID-19?

A new study by a team of researchers at the Keck School of Medicine, University of Southern California, USA, reports a potentially important therapeutic target in the form of a molecule called GRP78 that promotes the entry and protein production by many viruses. The team's paper has been published in the Journal of Biological Chemistry.

26 May 2021

New collaborative effort to produce anti-HIV monoclonal antibodies

The Hotung Molecular Immunology group at St George's, University of London has partnered with Leaf Expression Systems, a contract development and manufacturing organization, specializing in plant-based expression and production of proteins, to explore the feasibility of producing anti-HIV monoclonal antibodies at large scale.

25 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.

20 May 2021

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Researchers at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center found that monoclonal antibodies, a COVID-19 treatment administered early after infection, reduce the risk of hospitalization and death by 60 percent in people at high risk of suffering complications from the condition.

20 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai.

17 May 2021

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Although several monoclonal antibodies against the SARS-CoV-2 spike protein have been developed and clinically tested, little is known about antibodies to the nucleocapsid protein. In a paper published recently in the journal Nature Communications, researchers report a human monoclonal antibody that targets the nucleocapsid protein.

17 May 2021

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

The World Health Organization (WHO) has labeled the double mutant B.1.617 variant — first discovered in India —a variant of concern for its high transmission rate and ability to evade immune responses. New research posted to the preprint server bioRxiv finds B.1.617 can modestly reduce neutralizing antibody responses generated from the Pfizer-BioNTech vaccine.

16 May 2021

Monoclonal Antibody News and Research

Further Reading

Fluorescence-based assay for detecting SARS-CoV-2 neutralizing antibodies

Experimental monoclonal antibody could be a new weapon against HIV epidemic

The great promise of antiviral peptides against SARS-CoV-2

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

Using Sotrovimab to treat COVID-19 early

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

Reducing COVID-19 burden with monoclonal antibodies and vaccination

Could GRP78 be a therapeutic target against COVID-19?

New collaborative effort to produce anti-HIV monoclonal antibodies

Facets of SARS-CoV-2 infection and animal models

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Nanotechnology and COVID-19 diagnosis and treatment

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

Antibody to SARS-CoV-2 inhibits complement hyperactivation

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®